<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="section" /><meta name="keywords" content="Hyperlipidaemia; Lipid-regulating drugs; Hypercholesterolaemia; Cardiovascular disease: prevention: non-drug treatment; Familial hypercholesterolaemia" /><meta name="IX" content="Hyperlipidaemia; Lipid-regulating drugs; Hypercholesterolaemia; Cardiovascular disease: prevention: non-drug treatment; Familial hypercholesterolaemia" /><title>2.12 Lipid-regulating drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="2836.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="2836.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=2836.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="106048.htm" title="Previous: PROTEIN C CONCENTRATE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="33422.htm" title="Next: Statins">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_2836">2.12 Lipid-regulating drugs</h1><?highlighter on?><div id="pC" class="jN"><div><p>Preventative measures should be taken in individuals with a high risk of developing
cardiovascular disease (primary prevention) and to prevent recurrence
of events in those with established cardiovascular disease (secondary
prevention).</p><p>Individuals at high risk include those who already have atherosclerotic
disease, those with diabetes mellitus aged over 40 years, and those
with familial hypercholesterolaemia. The risk also increases with
age; those over 75 years are at particularly high risk, especially
if they smoke or have hypertension.</p><p>Preventative measures are also required for other individuals
who may be at high risk of developing atherosclerotic cardiovascular
disease; those with a 10-year risk of cardiovascular disease<sup class="footnote"><a title="Go to footnote" href="2836.htm#footnote112931">(1)</a></sup> of 20% or more stand to benefit most from
drug treatment. The risk is assessed on the basis of lipid concentration
as well as smoking status, blood pressure, gender, and age; other
risk factors, such as premature menopause, ethnicity, obesity, triglyceride
concentration, chronic kidney disease, impaired glucose tolerance,
and a family history of premature cardiovascular disease, should also
be taken into account when assessing risk in individual patients.</p><div id="_2836.2"><p>Patients with hypothyroidism should receive adequate thyroid
replacement therapy before assessing the requirement for lipid-regulating
treatment because correcting hypothyroidism itself may resolve the
lipid abnormality. Untreated hypothyroidism increases the risk of
myositis with lipid-regulating drugs.</p></div><p>Lowering the concentration of low-density lipoprotein
(LDL) cholesterol and raising high-density lipoprotein (HDL) cholesterol
slows the progression of atherosclerosis and may even induce regression.
All patients at high risk of cardiovascular disease should be advised
to make lifestyle modifications that include beneficial changes to
diet, exercise, weight management, alcohol consumption, and smoking
cessation. Lipid-regulating drug treatment must be combined with advice
on diet and lifestyle measures, lowering of raised blood pressure
(<a title="section: Hypertension and heart failure" href="2534.htm#_2534">section 2.5</a>), the use of low-dose aspirin (<a title="monograph: ASPIRIN (antiplatelet)" href="2803.htm#_2803">section 2.9</a>), and management of diabetes (<a title="section: Drugs used in diabetes" href="4080.htm#_4080">section 6.1</a>).</p><p>A <b>statin</b> reduces the risk of cardiovascular
disease events, irrespective of serum cholesterol concentration, and
is the drug of first choice for primary and secondary prevention of
cardiovascular disease. If statins are contra-indicated or not tolerated,
a <b>fibrate</b> or a <b>bile acid sequestrant</b> may be considered for <i>primary</i> or <i>secondary</i> prevention; <b>nicotinic acid</b> is also an option for <i>secondary</i> prevention. Fibrates, bile acid sequestrants,
or nicotinic acid should not be used in combination with a statin
for <i>primary</i> prevention of cardiovascular disease.
In secondary prevention of cardiovascular events, if a total cholesterol
concentration of less than 4 mmol/litre <i>or</i> a LDL-cholesterol
concentration of less than 2 mmol/litre is not achieved with initial
treatment, consider treating patients with a ‘high-intensity’ statin
(e.g. simvastatin or atorvastatin)—a ‘high-intensity’ statin is one
that produces a greater LDL-cholesterol reduction than simvastatin
40 mg; ‘high-intensity’ statins are associated with an increased risk
of muscle toxicity—see <a title="BNF:target-block: Statins muscle effects" href="33422.htm#_33422.3">Muscle Effects</a>. Patients with an acute coronary
syndrome should also receive treatment with a ‘high-intensity’ statin
where appropriate.</p><p>A statin is also the drug of first choice for treating hypercholesterolaemia
and moderate hypertriglyceridaemia. Severe hyperlipidaemia not adequately
controlled with a maximal dose of a statin may require the use of
an additional lipid-regulating drug such as <b>ezetimibe</b> or <b>colestyramine</b>; such treatment should generally
be supervised by a specialist.</p><p>A number of conditions, some familial, are characterised by
very high LDL-cholesterol concentration, high triglyceride concentration,
or both. <b>Fenofibrate</b> may be added to statin therapy
if triglycerides remain high even after the LDL-cholesterol concentration
has been reduced adequately; <b>nicotinic acid</b> may also
be used to further lower triglyceride or LDL-cholesterol concentration.</p><p>Combination of a statin with a fibrate or with nicotinic acid
carries an increased risk of side-effects (including rhabdomyolysis—see <a title="BNF:target-block: Statins muscle effects" href="33422.htm#_33422.3">Muscle Effects</a>) and should be used under
specialist supervision; monitoring of liver function and creatine
kinase should also be considered. The concomitant administration of
gemfibrozil with a statin increases the risk of rhabdomyolysis considerably—this
combination should <b>not</b> be used.</p><p>A statin
is recommended for all patients with familial hypercholesterolaemia.
A ‘high-intensity’ statin (e.g. rosuvastatin (initiated by a specialist),
simvastatin, or atorvastatin) should be considered in order to achieve
the recommended reduction in LDL-cholesterol concentration of greater
than 50% from baseline; a ‘high-intensity’ statin is one that produces
a greater LDL-cholesterol reduction than simvastatin 40 mg—‘high-intensity’
statins are associated with an increased risk of muscle toxicity—see <a title="BNF:target-block: Statins muscle effects" href="33422.htm#_33422.3">Muscle Effects</a>. Patients with
heterozygous familial hypercholesterolaemia who have contra-indications
to, or are intolerant of, statins should receive ezetimibe. The combination
of a statin and ezetimibe can be considered if a statin alone fails
to provide adequate control (or if intolerance limits dose titration),
and when a switch to an alternative statin is being considered. Patients
for whom statins and ezetimibe are inappropriate, should be referred
to a specialist for the consideration of treatment with a bile acid
sequestrant, nicotinic acid, or a fibrate.</p><p>The prescribing of drug therapy in homozygous familial hypercholesterolaemia
should be undertaken in a specialist centre.</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_33422"><a href="33422.htm" title="Statins">Statins</a></li><li id="_2837"><a href="2837.htm" title="Bile acid sequestrants">Bile acid sequestrants</a></li><li id="_127989"><a href="127989.htm" title="Ezetimibe">Ezetimibe</a></li><li id="_2843"><a href="2843.htm" title="Fibrates">Fibrates</a></li><li id="_2855"><a href="2855.htm" title="Nicotinic acid group">Nicotinic acid group</a></li><li id="_2862"><a href="2862.htm" title="Omega-3 fatty acid compounds">Omega-3 fatty acid compounds</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="106048.htm">Previous: PROTEIN C CONCENTRATE  </a> | <a class="top" href="2836.htm#">Top</a> | <a accesskey="]" href="33422.htm">Next: Statins</a> ►</div><div class="cF"><div class="footnote" id="footnote112931"><sup>(1)</sup>Cardiovascular disease risk may be determined from the <a title="BNF:topic: How to use the Cardiovascular Risk Prediction Charts for Primary Prevention" href="204016.htm#_204016">chart</a> issued by the
Joint British Societies (<i>Heart</i> 2005; <b>91</b> (Suppl V): v1–v52). The Joint British Societies’ ‘Cardiac Risk
Assessor’ computer programme may also be used to determine cardiovascular
disease risk.</div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>